Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed clinical data from the positive Phase 2b portion of the seamless Phase 2/3 MOBILITY trial of sarilumab (REGN88/SAR153191) in rheumatoid arthritis (RA) will be presented at a late-breaking poster session at the upcoming American College of Rheumatology (ACR) Annual Scientific Meeting, which will take place from November 5-9 in Chicago. Sarilumab is a novel, high-affinity, subcutaneously administered, fully-human antibody targeting the interleukin-6 receptor (IL-6R)
The poster will be presented on Tuesday, November 8 from 9 AM to 6 PM EST. The abstract, titled "Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study," is available on the ACR website at: http://acr.confex.com/acr/2011/webprogram/Paper24502.html.
Gut bacteria changes may foreshadow rheumatoid arthritis